This is a preview blog series on what you can expect when subscribing to my "Biotech Analysis Central" service marketplace. For the full article you must subscribe to my service. This is just an intro of two snippets on the research articles that are written. Thus far, there are about 100+ research reports on both both small-cap and mid-cap biotech stocks with full analysis of the pipeline, catalysts, financials, and clinical trial analysis. If you want to read more then please subscribe to my marketplace service. As always I offer a 2-week free trial just to show you how helpful my service is. You can cancel anytime before the 2-week free trial is up and never be charged a dime.
First Section Of Marketplace Article (This article piece was originally written on February 3, 2020)
The next article I wanted to discuss for the "Biotech Analysis Central Stock Insight Series" is a biotech by the name of Trillium Therapeutics (TRIL). There are several reasons why I am going over Trillium Therapeutics next. One main reason is because the mechanism of action of targeting CD47 has been proven by a peer. This target involves the next generation of checkpoint inhibitor therapy. Based on this potential alone, Trillium should be valued equal to if not higher than its equivalent biotech. Besides the CD47 products, it boasts a 2nd generation STING agonist. Lastly, it had already raised $117 million just the other week. That means no near-term risk of a cash raise. Based on all these prospects, I believe that Trillium is significantly undervalued.
Conclusion Of Marketplace Article
The Final Verdict is that Trillium Therapeutics is a good company to own. That's because it doesn't just have one, but two CD47 products. Forty Seven set up the proof of concept for the field, but based on what I have shown you above, Trillium has several advantages over it with its drugs. TTI-621/TTI-622 are better in terms of safety (no red blood cell binding causing anemia) and have seen amazing results at 100X lower doses. Just the hematological malignancies market alone is huge. Consider the fact that the the global market opportunity for non-Hodgkin Lymphoma (NHL) will reach $10.8 billion by 2025. Then you have other market opportunities, like the global MDS market and AML market which are expected to reach $2.4 billion and $2.2 billion in the coming years respectively. I believe the most important item to consider is the low market cap that Trillium has, which is only $283 million. Especially, when you consider the fact that the main peer Forty Seven Inc. has a market cap of $1.85 billion. If Trillium can post a positive set of results from both TTI-621 and TTI-622 in mid-2020, then there is a chance that Trillium's stock will start to close the gap to FTSV. The reason why is because of the safety and efficacy that has been observed with Trillium's CD47 products, which I believe are superior to FTSVs, even at the early stages of development.
Disclosure: I am/we are long TRIL.